Grufity logoGrufity logo
StocksFundsSearch Filings

Neurocrine Biosciences Inc Stock Research

NBIX

91.22USD-0.96(-1.04%)Market Closed

Market Summary

USD91.22-0.96
Market Closed
-1.04%

NBIX Alerts

NBIX Stock Price

NBIX RSI Chart

NBIX Valuation

Market Cap

8.9B

Price/Earnings (Trailing)

138.97

Price/Sales (Trailing)

5.56

EV/EBITDA

79.33

Price/Free Cashflow

37.48

NBIX Price/Sales (Trailing)

NBIX Profitability

Operating Margin

98.90%

EBT Margin

14.37%

Return on Equity

9.05%

Return on Assets

6.52%

Free Cashflow Yield

2.67%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

1.6B

Revenue Y/Y

35.35%

Revenue Q/Q

2.04%

NBIX Earnings

Earnings (TTM)

64.0M

Earnings Y/Y

-651.08%

Earnings Q/Q

-186.07%

Price Action

52 Week Range

88.23129.29
(Low)(High)

Last 7 days

-3.0%

Last 30 days

-11.2%

Last 90 days

-11.0%

Trailing 12 Months

1.5%

NBIX Financial Health

Current Ratio

2.7

NBIX Investor Care

Shares Dilution (1Y)

2.09%

Diluted EPS (TTM)

0.61

Peers (Alternatives to Neurocrine Biosciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
AMGN
115.9B
26.2B
 -9.16% -12.25%
14.64
4.43
 -0.48% 38.34%
GILD
96.2B
27.0B
 -7.94% 24.63%
17.23
3.56
 -1.56% 23.65%
MRNA
48.5B
15.1B
 -3.43% -7.04%
10.13
3.22
 -33.37% -67.32%
BIIB
43.1B
10.1B
 3.69% 46.24%
13.77
4.27
 -6.61% 115.98%
MID-CAP
NBIX
8.9B
1.6B
 -11.20% 1.54%
138.97
5.56
 32.38% -10.36%
DNLI
4.1B
-
 22.94% 24.01%
-11.06
37.77
 122.90% -29.67%
BEAM
2.4B
76.7M
 5.96% -0.58%
-7.62
31.42
 41.73% -32.75%
BBIO
2.2B
107.9M
 -3.78% 107.70%
-4.55
20.44
 54.84% 17.36%
SMALL-CAP
RCUS
1.6B
119.0M
 22.46% 21.04%
-5.77
13.53
 -69.61% -584.39%
REPL
1.1B
10.0M
 16.71% 38.03%
-6.34
110.4
 215.65% -47.65%
NVAX
622.2M
-
 -4.25% -84.68%
-0.54
0.31
 72.89% 12.32%
FATE
503.7M
136.9M
 -11.86% -77.13%
-2.14
3.68
 116.83% -0.93%
SGMO
210.2M
241.0M
 -21.74% -64.41%
-1.65
0.87
 113.96% 27.87%
VXRT
162.7M
697.0K
 67.22% -64.71%
-1.51
233.45
 47.98% -35.48%
IBIO
9.3M
-
 -31.01% -87.63%
-0.12
3.21
 0.51% -129.47%

Financials for Neurocrine Biosciences

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue7.4%1,5991,4891,3891,2971,208
  S&GA Expenses5.6%795753726695655
EBITDA116.6%23610946.00129-
EBITDA Margin102.1%0.16*0.08*0.04*0.11*-
Earnings Before Taxes-58.3%89.0021482.0015.0096.00
EBT Margin142.7%0.14*0.06*0.01*0.08*-
Interest Expenses-21.1%6.007.0013.0018.0022.00
Net Income-58.6%64.0015558.0012.0071.00
Net Income Margin147.6%0.10*0.04*0.01*0.06*-
Free Cahsflow82.4%323177133102-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-0.4%2,3602,3692,1432,0062,145
  Current Assets-1.4%1,4331,4541,2061,0191,018
    Cash Equivalents-57.6%112263212163270
  Inventory-4.8%33.0035.0037.0029.0029.00
  Net PPE7.2%63.0059.0061.0067.0064.00
Liabilities2.2%675661599582753
  Current Liabilities-30.4%374538485286254
Shareholder's Equity-1.4%1,6851,7081,5451,4231,391
  Retained Earnings-18.8%-483-406-495-564-547
  Additional Paid-In Capital2.3%2,1712,1222,0542,0001,948
Shares Outstanding1.0%98.0097.0096.0096.0096.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-25.0%255339201164129
  Share Based Compensation1.7%176173165159138
Cashflow From Investing-5.9%-187-177-37.80-102-224
Cashflow From Financing0.9%-232-234-257-26118.00

Risks for NBIX

What is the probability of a big loss on NBIX?

85.8%

Probability that Neurocrine Biosciences stock will be more than 20% underwater in next one year

49.6%

Probability that Neurocrine Biosciences stock will be more than 30% underwater in next one year.

17.7%

Probability that Neurocrine Biosciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NBIX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Neurocrine Biosciences was unfortunately bought at previous high price.

Drawdowns

Returns for NBIX

Cumulative Returns on NBIX

21.2%

10-Year Cumulative Returns

10.2%

7-Year Cumulative Returns

-0.6%

5-Year Cumulative Returns

-8.5%

3-Year Cumulative Returns

What are the long-term rolling returns for NBIX?

FIve years rolling returns for Neurocrine Biosciences.

Annualized Returns

Which funds bought or sold NBIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Toroso Investments, LLC
new
-
416,000
416,000
 0.01%
2023-05-23
Front Row Advisors LLC
reduced
-1.49
-1,000
7,000
 -%
2023-05-22
Raleigh Capital Management Inc.
added
78.38
2,262
6,681
 -%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-9.57
-16,845,700
55,248,300
 0.02%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
377,000
 0.02%
2023-05-22
PUTNAM INVESTMENTS LLC
unchanged
-
-182,830
1,043,690
 -%
2023-05-22
American Trust
reduced
-39.97
-383,161
396,782
 0.03%
2023-05-19
Coppell Advisory Solutions LLC
sold off
-100
-50,523
-
 -%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-11.19
-6,804,000
20,696,000
 0.03%
2023-05-18
JPMORGAN CHASE & CO
reduced
-0.65
-40,960,400
218,231,000
 0.03%

1–10 of 42

Latest Funds Activity

Are funds buying NBIX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NBIX
No. of Funds

NBIX Alerts

Neurocrine Biosciences News

Defense World
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by LPL ....
Defense World,
22 hours ago
Best Stocks
Neurocrine Biosciences Receives Moderate Buy Rating and ....
Best Stocks,
26 hours ago
MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus ....
MarketBeat,
47 hours ago
PR Newswire
Neurocrine Biosciences Announces Publication of Full KINECT ....
PR Newswire,
8 days ago
Yahoo Finance
Are Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?.
Yahoo Finance,
8 days ago
MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by First ....
MarketBeat,
11 days ago
Best Stocks
BioTechne Announces Expansion of Advanced Cell Diagnostics ....
Best Stocks,
11 days ago
PR Newswire
Neurocrine Biosciences Presents INGREZZA® (valbenazine ....
PR Newswire,
12 days ago
MarketBeat
Motley Fool Asset Management LLC Invests $206000 in Neurocrine ....
MarketBeat,
14 days ago
Simply Wall St
Pulling back 5.9% this week, Neurocrine Biosciences' NASDAQ:NBIX) one-year decline in earnings may be coming into investors focus.
Simply Wall St,
18 days ago
PR Newswire
Neurocrine Biosciences Reports First Quarter 2023 Financial Results.
PR Newswire,
24 days ago
Nasdaq
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue ....
Nasdaq,
24 days ago
Investor's Business Daily
Composite Rating For Neurocrine Biosciences Jumps To 96 ....
Investor's Business Daily,
25 days ago
PR Newswire
Neurocrine Biosciences Supports the Mental Health Community ....
PR Newswire,
26 days ago
StockNews.com
NBIX: Healthy Returns: This A Rated Healthcare Stock Is a Must ....
StockNews.com,
29 days ago
Nasdaq
Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline.
Nasdaq,
30 days ago

Schedule 13G FIlings of Neurocrine Biosciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
janus henderson group plc
2.5%
2,415,638
SC 13G/A
Feb 09, 2023
vanguard group inc
9.72%
9,340,295
SC 13G/A
Jan 23, 2023
blackrock inc.
13.1%
12,627,403
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
4.5%
4,359,645
SC 13G/A
Feb 10, 2022
vanguard group inc
9.26%
8,787,991
SC 13G/A
Feb 10, 2022
janus henderson group plc
7.8%
7,445,839
SC 13G/A
Jan 27, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A
Jan 26, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A
Aug 10, 2021
fmr llc
-
0
SC 13G/A
Apr 12, 2021
blackrock inc.
11.7%
10,989,646
SC 13G/A

NBIX Fair Value

Neurocrine Biosciences fair value in different scenarios

The table shows the Fair Value estimates for Neurocrine Biosciences for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

58.60

-35.76%

74.82

-17.98%

138.36

51.68%

234.88

157.49%

403.18

341.99%
Current Inflation

53.71

-41.12%

67.54

-25.96%

121.76

33.48%

203.17

122.73%

345.03

278.24%
Very High Inflation

47.68

-47.73%

58.74

-35.61%

102.21

12.05%

166.50

82.53%

278.42

205.22%

Historical Neurocrine Biosciences Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Neurocrine Biosciences

View All Filings
Date Filed Form Type Document
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
8-K
Current Report
May 11, 2023
4/A
Insider Trading

Latest Insider Trading transactions for NBIX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-01
Cooke Julie
sold
-1,184,050
103
-11,397
chief human resources officer
2023-05-01
RASTETTER WILLIAM H
sold
-436,135
101
-4,300
-
2023-05-01
RASTETTER WILLIAM H
acquired
96,913
12.71
7,625
-
2023-04-25
Cooke Julie
sold
-10,382
103
-100
chief human resources officer
2023-04-24
ROBERTS EIRY
sold
-1,490,060
103
-14,400
chief medical officer
2023-04-21
RASTETTER WILLIAM H
sold
-633,787
105
-6,034
-
2023-04-21
RASTETTER WILLIAM H
acquired
136,823
12.71
10,765
-
2023-04-19
RASTETTER WILLIAM H
acquired
20,463
12.71
1,610
-
2023-04-19
RASTETTER WILLIAM H
sold
-94,818
105
-903
-
2023-02-08
GORMAN KEVIN CHARLES
sold
-237,185
104
-2,274
chief executive officer

1–10 of 50

About Neurocrine Biosciences

Kevin C. Gorman
www.neurocrine.com
900
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Income Statement

2023-03-31
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Revenues$ 420.4$ 310.6
Operating expenses:  
Cost of revenues8.54.6
Research and development139.5102.2
Acquired in-process research and development143.90.0
Selling, general and administrative242.7200.7
Total operating expenses534.6307.5
Operating (loss) income(114.2)3.1
Other income (expense):  
Interest expense(1.1)(2.6)
Unrealized gain on equity security investments2.219.9
Investment income and other, net9.81.0
Total other income, net10.918.3
(Loss) income before (benefit from) provision for income taxes(103.3)21.4
(Benefit from) provision for income taxes(26.7)7.5
Net (loss) income(76.6)13.9
Foreign currency translation adjustments, net of tax1.20.0
Unrealized gain (loss) on debt securities available-for-sale, net of tax4.0(7.6)
Comprehensive (loss) income$ (71.4)$ 6.3
(Loss) earnings per share:  
Basic (in USD per share)$ (0.79)$ 0.15
Diluted (in USD per share)$ (0.79)$ 0.14
Weighted-average shares outstanding:  
Basic (in shares)97.195.3
Diluted (in shares)97.197.6
Net product sales  
Revenues:  
Revenues$ 415.3$ 305.0
Collaboration revenues  
Revenues:  
Revenues$ 5.1$ 5.6

NBIX Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 103.8$ 262.9
Debt securities available-for-sale790.8726.4
Accounts receivable391.6350.0
Inventories33.435.1
Other current assets113.279.1
Total current assets1,432.81,453.5
Deferred tax assets337.4305.9
Debt securities available-for-sale244.6299.4
Right-of-use assets84.487.0
Equity security investments135.7102.1
Property and equipment, net62.858.6
Intangible assets, net37.237.2
Other assets24.925.0
Total assets2,359.82,368.7
Current liabilities:  
Accounts payable and accrued liabilities355.7347.6
Convertible senior notes0.0169.4
Other current liabilities18.420.7
Total current liabilities374.1537.7
Convertible senior notes169.50.0
Noncurrent operating lease liabilities90.493.5
Other long-term liabilities41.329.7
Total liabilities675.3660.9
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding0.00.0
Common stock, $0.001 par value; 220.0 million shares authorized; 97.5 million and 96.5 million shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,170.52,122.4
Accumulated other comprehensive loss(2.7)(7.9)
Accumulated deficit(483.4)(406.8)
Total stockholders’ equity1,684.51,707.8
Total liabilities and stockholders’ equity$ 2,359.8$ 2,368.7